[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Chidambaram S.B., Anand N., Varma S.R., Ramamurthy S., Vichitra C., Sharma A., Mahalakshmi A.M., Essa M.M
The key anti-inflammatory effects included: Modulation of macrophage activation states Decreased reactive nitrogen species production Reduced efferocytotic activity in treated cells Lower expression of pro-inflammatory mediators Research on corneal injuries found TB-500 suppressed multiple inflammatory mediators while maintaining bacterial clearance when combined with antibiotics
Colvin et al., 2020), and to disrupt the normal activity of dopamine neurons during drug engagement (Egecioglu et al., 2013a
On the regulatory side: neither BPC-157 nor TB-500 is approved by the FDA or EMA for human use
A composite control group containing equal amounts of these three antihyperglycemics was also included, as was a control group of individuals who continued with their non-GLP-1RA antihyperglycemic regimen without additional new therapy (usual care)